Riyue Bao, PhD
UPMC Hillman Cancer Center, University of Pittsburgh
Research Project:
Tumor Cell Signaling May Impact Immunotherapy Response for Lung Squamous Cell Cancer
Grant Awarded:
- Innovation Award
Research Topics:
- basic biologic mechanisms
- biomarkers
- clinical research
- combination therapies experimental therapeutics
- computational biology
- imaging radiology
- immunology immunotherapy
Research Disease:
- lung cancer
Immunotherapies have revolutionized treatment for patients with advanced lung squamous cell carcinoma. However, most patients do not experience a long-lasting response. We are studying a tumor-cell pathway called p38 MAPK, which we believe plays a key role in resistance to a main type of immunotherapy called immune checkpoint inhibitors (ICI). By understanding how p38 MAPK contributes to this resistance, we hope to improve the effectiveness of ICI and develop new strategies to improve patient outcomes. Our research could pave the way for a large-scale, multi-year initiative aimed at enhancing anti-tumor immunity and overcoming treatment resistance in this challenging disease.
Page last updated: October 7, 2024
2X Your Lifesaving Impact
We all play a part in protecting lung health. For a limited time, your gift will be DOUBLED to defeat lung disease!
